U.S. FTC Seeks More Data About Aussie CSL Buy Of Talecris
This article was originally published in PharmAsia News
Executive Summary
The U.S. Federal Trade Commission has requested more information from Australia's CSL about its bid to take over Talecris Biotherapeutics of the United States. CSL, the world's largest maker of plasma products, said such a request was common for mergers that could have U.S. antitrust implications. CSL, which has proposed buying Talecris for $2 billion, said both firms are cooperating with the FTC as it considers the buyout. (Click here for more